-
Views
-
Cite
Cite
Study Showed Oxaliplatin Improved Colon Cancer Patient Survival, JNCI: Journal of the National Cancer Institute, Volume 104, Issue 3, 8 February 2012, Page 1, https://doi.org/10.1093/jnci/djs028
Close - Share Icon Share
Extract
Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published Jan. 20 in The Journal of the National Cancer Institute.
Colon cancer is a leading global cause of both illness and death, with an estimated 101,340 cases among Americans in 2011. Roughly one-third of diagnoses are stage III or node-positive disease. In randomized clinical trials (RCTs), adding oxaliplatin to adjuvant 5FU is known to improve outcomes of patients with stage III colon cancer. But the effect of this combined therapy outside RCTs is unknown. In addition, fewer than 2% of patients with the cancer enroll in RCTs, and participants are known to be generally younger, healthier and less racially diverse than the overall cancer patient population.
In order to determine the effects of combined therapy in stage III colon cancer patients in the general population, Hanna K. Sanoff M.D., an assistant professor of Medicine, Hematology and Oncology at the University of Virginia School of Medicine and colleagues, gathered data from patients using the Surveillance, Epidemiology, and End Results registry linked to Medicare claims (SEER-Medicare), among other cancer registries. All patients had stage III colon cancer, received chemotherapy within 120 days of surgery, and were age 75 years or younger. Overall survival (OS) was then compared between patients treated with combined therapy and standard chemotherapy.
